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Yinghong Li et al.3081. Introduction
Chronic hepatitis C virus (HCV) infection has become a major
public health burden worldwide. The World Health Organization
(WHO) reported that over 3% of the global population with
approximately 180 million individuals is estimated to be infected
with HCV, with a 3–4 million new cases appearing every year
globally1,2. Among all countries, China accommodates the largest
HCV-infected population, with more than 41 million people
infected, and the incidence rate is rising year by year2. In nearly
85% of the cases, the disease progresses into chronicity, and 30
percent of the cases may progress to liver cirrhosis, end-stage liver
disease and hepatocellular carcinoma (HCC)3.
There is no vaccine to prevent HCV infection. The standard
therapy for HCV in the clinic is the combination of pegylated-
interferon with ribavirin4,5. The regimen is only effective in
approximately 40% of patients infected with HCV genotype 1,
the prevalent HCV genotype in the United States, Europe, and
China, and is associated with signiﬁcant side effects3. The
introduction of Telaprevir and Boceprevir was temporarily effec-
tive with HCV patients, but drug-resistant mutations soon
appeared6–9. Sofosbuvir, a new HCV NS5B RNA polymerase
inhibitor approved by FDA in 2013 showed promise in dealing
with drug-resistant HCV10. However, a S282T mutation in NS5B
was found in genotype 1a, 1b and 2a replicons, and caused a
reduced susceptibility to sofosbuvir, again raising the need for new
drugs with novel modes of action11.
Matrine (1, Fig. 1), a quinolizidine natural product extracted
from Sophora ﬂavescens, has been used clinically for HBV
treatment for decades and has a novel mechanism of action12,13.
Clinical reports showed that compound 1 was also effective for
HCV patients in China14. Bearing a unique 4-ring core scaffold,
compound 1 strongly provoked our interest to explore its anti-
HCV structure-activity relationship (SAR) in an effort to discover
a new chemical entity (NCE) against HCV with a novel mechan-
ism. SAR studies have been carried out in our lab, revealing that
the 5S conﬁguration in the core scaffold is beneﬁcial for anti-HCV
activity15,16. In the present study, the 5S conﬁguration was
maintained and further SAR analysis was directed toward the
carbon-carbon double bond in sophocarpine (2, Fig. 1), another
natural product extracted from Sophora ﬂavescens. Based on this
strategy, a series of (E)-Δβγ/Δαβ-sophocarpinic acid (3/4, Fig. 1)
derivatives bearing a D-seco 3-ring scaffold were synthesized and
evaluated for their anti-HCV activities.Figure 1 The chemical structures of marine (1), sophocarpine (2)2. Results and discussion
2.1. Chemistry
As showed in Scheme 1, compound 2, as the starting material, was
hydrolyzed in strong base and formed an isomeric mixture of 3 and 4.
The target compounds (E)-12-N-substituted-Δβγ/Δαβ-sophocarpinic
acids (9/10) were acquired by using a three-step sequence including
carboxyl protection with diphenyldiazomethane as the protective agent,
12-N-alkylation or acylation in the presence of potassium carbonate,
and deprotection in m-cresol15–19, with overall yields of 5%–12%. The
regio-isomers were separated before alkylation or acylation.
To gain sophocarpinic acid derivatives without the double bond,
2 was reﬂuxed in aqueous base as illustrated in Scheme 2 to gain
the key intermediate 11, which was hydrolyzed in strong base to
form a 3-ring scaffold product 12, followed by a three-step
sequence including carboxyl protection via diphenyldiazomethane,
12-N-alkylation in the presence of potassium carbonate and
deprotection in m-cresol to gain the desired product 15 in an
overall yield of 16.1%15–19. Matrine derivatives 16a-d (Table 1) as
a class of anti-HBV agents were prepared as previously reported17.2.2. SAR analysis for anti-HCV activity in vitro
All the synthesized compounds were tested for their anti-HCV
activity and cytotoxicity in Huh7.5 cells using speciﬁc real-time
RT-PCR assay, as described in our previous publication20. Anti-
HCV activity was evaluated by measuring both EC50 (for anti-
HCV activity) and TC50 (for cytotoxicity) values. As a key
indication, the selectivity index (SI) was calculated as a ratio of
TC50 to EC50. Anti-HCV activity of a given compound was
estimated by combining its EC50 value with its SI. Twenty-two
sophoridinic acid or sophoridine analogs and their anti-HCV
effectiveness are shown in Tables 1 and 2.
The SAR study for anti-HCV activity was initially focused on
the inﬂuence of the substitutions on ring D while the 4-ring
scaffold was unchanged. As indicated in Table 1, matrine
compounds 16a-c afforded similar or lower SI values compared
to compound 1, while compound 16d bearing a methylamino
showed a higher SI value, which hinted that suitable substitutions
on ring D could enhance the activity against HCV.
Table 2 disclosed the SAR analysis on the D-meso 3-ring
scaffold derivatives. The compounds bearing a carbon-carbon, (E)-Δβγ sophocarpinic acid (3) and (E)-Δαβ sophocarpinic acid (4).
Scheme 1 Synthetic routes for N-substituted sophocarpinic acid analogs. Reagents and conditions: (a) 10% KOH/H2O, reﬂux, 7 h; then 3 mol/L
HCl, pH 5–6; (b) diphenyldiazomethane, MeOH/petroleum ether(boiling range 30–60 1C), overnight; (c) (1) substituted benzyl chloride/bromine
or benzenesulfonyl chloride, CH2Cl2 or MeCN, K2CO3, r.t., overnight; (2) ﬂash column chromatography; (d) m-cresol, 80 1C, 8–9 h.
Scheme 2 Synthetic routes for 12-N-benzyl-β-hydroxylmatrinic acid (15). Reagents and conditions: (a) 5% KOH/H2O, reﬂux, 8 h; then 3 mol/L
HCl, pH 5–6; (b) 10% KOH/H2O, reﬂux, 7 h; then 3 mol/L HCl, pH 5–6; (c) diphenyldiazomethane, MeOH/petroleum ether (boiling range 30–
60 1C), overnight; (d) benzyl bromide, MeCN, K2CO3, r.t., overnight; (e) m-cresol, 80 1C, 8–9 h.
Synthesis and biological evaluation of anti-HCV agents 309double bond on the side chain, speciﬁcally, (E)-12-N-substituted-
Δβγ-sophocarpinic acids (9a–k) and their isomers (E)-12-N-sub-
stituted -Δαβ-sophocarpinic acids (10a–f), were evaluated in this
study. First, the inﬂuence of the substituents on the 12-nitrogen
atom in the (E)-Δβγ-sophocarpinic acids was examined. The results
showed that 12-N-benzyl derivatives 9a–c showed anti-HCV
activities similar to or lower than compound 1, and most of the
compounds in the 12-N-benzenesulfonyl series (9d–k) had low
activities against HCV, except that compound 9h and 9j showed
signiﬁcantly higher activity than compound 1 with SI values of
70.3 and 30.9, respectively. The results suggested that theintroduction of CF3 or CN on the sulfonylphenyl ring might be
beneﬁcial for the anti-HCV activity.
In the case of the (E)-Δαβ-sophocarpinic acids derivatives
10a–f, most showed decreased or similar anti-HCV activities as
compared to compound 1, regardless of the electron-donating or
electron-withdrawing groups on the phenyl ring, which hinted that
a Δβγ analog could do better than its Δαβ isomer in anti-HCV area.
The introduction of OH at the double bond could decrease anti-
HCV activity, as compared with product 15 and compound 9b.
All together, it appeared that a D-meso 3-ring structure scaffold
was more favorable than a 4-ring scaffold, and the introduction of
Yinghong Li et al.310an electron-withdrawing group on the phenyl ring in 12-N-
benzenesulfonyl Δβγ-sophocarpinic acid derivatives was beneﬁcial
for anti-HCV activity.Table 2 SAR for anti-HCV activity of sophocarpinic acid derivativ
Compd. R T
(μ
1 4
9a –CH2PhCH3-o
9b –CH2Ph 4
9c –CH2PhBr- p
9d –SO2PhNO2-p
9e –SO2Ph 4
9f –SO2PhCH3-p 4
9g –SO2PhOCH3-p 4
9h –SO2PhCF3-p
9i –SO2PhCl-o
9j –SO2PhCN-m
9k –SO2Ph(NHCOCH3)-p
10a –CH2PhNO2- p 4
10b –SO2Ph 4
10c –SO2PhCH3-p
10d –SO2PhCl-o
10e –SO2Ph(NHCOCH3)-p
10f –SO2PhOCH3-p
15 –CH2Ph 4
RBV
aCytotoxic concentration required to inhibit Vero cell growth by 50%.
bConcentration required to inhibit CVB3 growth by 50%.
cSelectivity Index values equaled to TC50/EC50.
Table 1 SAR for anti-HCV activity of matrine analogues.
No R1 R2 TC50
(μg/mL) a
EC50
(μg/mL)b
SIc
1 H H 41000 98.04 410.2
16a H OCH2CH3 41000 104.62 49.6
16b OCH2Ph OCH2Ph 49.87 5.60 8.9
16c OH OCOCH2Cl 54.90 437.04 o1.5
16d H NHCH3 543.70 31.07 17.5
RBV 2000 292.46 6.84
aCytotoxic concentration required to inhibit Vero cell growth
by 50%.
bConcentration required to inhibit CVB3 growth by 50%.
cSelectivity index values equaled to TC50/EC50.3. Conclusions
In searching for novel anti-HCV agents, 22 sophocarpinic acid or
matrine derivatives were synthesized and evaluated for their anti-
HCV activities in vitro with 1 as the lead. Among these
derivatives, compounds 9h and 9j exhibited the most potent
antiviral activities against HCV with SI values of 70.3 and 30.9,
respectively. SAR revealed that (i) sophocarpinic acids with a D-
seco 3-ring structure scaffold are more favorable than matrines
with a 4-ring scaffold; (ii) introduction of an electron-withdrawing
group on the phenyl ring in 12-N-benzenesulfonyl substituted Δβγ-
sophocarpinic acid derivatives is beneﬁcial for activity. In addi-
tion, compounds 9h and 9j showed satisfactory activity against
coxsackievirus type B3 (CVB3) and CVB6 in our earlier study,
plus good pharmacokinetic proﬁles with low toxicity in vivo19. All
together, 9h and 9j are highly recommended to be further
developed as broad-spectrum antiviral drug candidates.4. Experimental
4.1. Chemistry
Melting point (mp) was obtained with an MPA 100 OptiMelt
automated melting point system (Stanford Research Systems,
California, USA) and uncorrected. 1H NMR spectra wases.
C50
g/mL)a
EC50
(μg/mL)b
SIc
1000 98.04 410.2
726.98 155.66 4.7
1000 49.3 20.3
357.41 24.36 14.7
380.7 74.0 5.14
1000 257.55 43.9
1000 112.06 48.9
1000 165.21 4 6.1
530.07 7.54 70.3
876.08 134.58 6.5
123.08 3.98 30.9
65.77 2.80 23.5
1000 52.82 418.9
1000 59.65 416.8
171.29 25.02 6.8
404.64 241.27 1.68
552.03 222.06 2.5
700.4 291.8 2.4
1000 4333.3 3
2000 292.46 6.84
Synthesis and biological evaluation of anti-HCV agents 311performed on a Varian Inova 400 MHz spectrometer (Varian, San
Francisco, CA) or 500 MHz spectrometer (AV500-III, Brvker,
Swiss), with Me4Si as internal standard. ESI high-resolution mass
spectra (HRMS) were recorded on an AutospecUItima-TOF mass
spectrometer (Micromass UK Ltd., Manchester, UK). Flash
chromatography was performed on CombiﬂashRf 200 (Teledyne,
Nebraska, USA), particle size 0.038 mm.
Compound 2 with purity over 98.5% was purchased from the
Yanchi Dushun Biological and Chemical Co., Ltd. (Shanxi, China)
and the Ningxia Zijinghua Pharmacy Co., Ltd. (Ningxia, China).
Target compounds 9b-c, 9e–k and 10b–f were prepared as a
family of anti-CVB3 inhibitors19.4.1.1. General procedures for 9 and 10
Compound 2 (12.3 g, 50 mmol, 1 equiv.) was added to a solution
of KOH (33.6 g, 600 mmol) in H2O (300 mL). The reaction
mixture was heated and reﬂuxed for 7 h and then stirred at room
temperature overnight. The reaction solution was cooled with an
ice–water bath and was acidiﬁed with HCl (3 mol/L) to pH 5–6.
The solvent was removed in vacuo, and the residue was
recrystallized in methanol to give an isomer mixture of 3 and 4.
A mixture of diphenylmethanone hydrazone (14.7 g, 75 mmol,
1.5 equiv.) and electrolytic manganese dioxide (13.04 g,
150 mmol, 3 equiv.) in petroleum ether (boiling range 30–60 1C)
was heated at reﬂux for 0.5 h, and the mixture was ﬁltered. The
ﬁltrate was added to the solution of 3 and 4 in methanol, and the
mixture was then stirred overnight at room temperature. A
corresponding isomer mixture of 5 and 6 was obtained and was
used directly in the next reaction without further puriﬁcation.
Anhydrous K2CO3 (3.5 equiv.) and benzyl bromine, or sulfonyl
chloride (1 equiv.) were added to the solution of 5 and 6 in
dichloromethane or MeCN (50 mL), and the reaction solution was
then stirred at room temperature until TLC analysis showed
completion of the reaction. The reaction mixture was ﬁltered and
the ﬁltrate was evaporated to afford a mixture of 7 and 8, which
were obtained by splitting of the mixture with ﬂash column
chromatography on silica gel with ethyl acetate and cyclohexane
as the eluents. Compound 7 was then dissolved in m-cresol
(10 mL), and the reaction mixture was stirred at 80 1C for 8–9 h.
It was then cooled, and methylisobutylketone (30 mL) was added.
The resulting solution was extracted with H2O (50 mL 3), and
the combined extracts were evaporated to afford the crude
compound, which was puriﬁed by ﬂash column chromatography
on silica gel with dichloromethane and methanol as the eluents, to
afford 9. Compound 10 was obtained from compound 8 by the
same method.
(E)-12-N-(o-Methylbenzyl)-Δβγ- sophocarpinic acid (9a): white
solid (0.6 g, 6.5%), mp 98–100 1C; 1H NMR (400 MHz, CD3OD):
δ 7.137.31 (m, 4H), 5.956.06 (m, 1H), 5.30 (dd, 1H, J¼9.2,
15.2 Hz), 4.46 (m, 1H), 3.033.10 (m, 3H), 2.99 (d, 2H,
J¼7.2 Hz), 2.822.93 (m, 2H), 2.422.61 (m, 3H),
2.312.33 (m, 3H), 2.19 (s, 1H), 1.872.03 (m, 3H),
1.411.79 (m, 7H); HRMS: calcd. for C23H33N2O2 (MþH)þ
369.2542, found 369.2529.
(E)-12-N-(p-Nitrobenzenesulfony)-Δβγ-sophocarpinic acid (9d):
white solid (2.2 g, 9.8%), mp 176179 1C; 1H NMR (400 MHz,
CD3OD): δ 8.36 (d, 2H, J¼8.8 Hz), 7.99 (d, 2H, J¼8.8 Hz),
5.445.47 (m, 2H), 3.76 (dd, 1H, J¼5.0, 11.2 Hz), 3.423.55
(m, 1H), 3.293.37 (m, 1H), 3.073.15 (m, 1H), 2.93 (d, 2H,
J¼5.0 Hz), 2.79 (d, 1H, J¼11.2 Hz), 2.682.69 (m, 1H),
2.502.54 (m, 1H), 1.902.11 (m, 3H), 1.301.83 (m, 8H);HRMS: calcd. for C21H28N3O6S (MþH)þ 450.1693, found
450.1710.
(E)-12-N-(p-Nitrobenzyl)-Δαβ-sophocarpinic acid (10a): white
solid (0.95 g, 9.5%), mp 139141 1C; 1H NMR (400 MHz,
CD3OD): δ 8.128.15 (m, 2H), 7.517.57 (m, 2H),
6.977.04 (m, 1H), 5.85 (d, 1H, J¼15.0 Hz), 4.23 (d, 1H,
J¼14.8 Hz), 3.273.47 (m, 4H), 2.903.01 (m, 3H), 2.792.85
(m, 1H), 2.472.78 (m, 3H), 2.192.22 (m, 1H), 1.932.08 (m,
2H), 1.651.88 (m, 7H); HRMS: calcd. for C22H30N3O4
(MþH)þ 400.2236, found 400.2217.
4.1.2. Procedures for 12-N-benzyl-β-hydroxyl sophocarpinic
acid (15)
To a solution of KOH (33.6 g, 0.6 mol) in water (600 mL) was
added 2 (12.3 g, 0.05 mol) with stirring at room temperature. The
reaction mixture was reﬂuxed for 8 h, then cooled down to 0 1C
and neutralized with 3 mol/L HCl. After concentrated in vacuo,
MeOH (150 mL) was added, insoluble solid was removed by
ﬁltration, and the ﬁltrate was concentrated under reduced pressure.
The residue was puriﬁed with ﬂash column chromatography on
silica gel using CH2Cl2/MeOH as eluent to give 11 (6.2 g, 47%) as
white solid.
Compound 11 (1 equiv.) was added to a solution of KOH
(10%) in water. The reaction mixture was reﬂuxed for 9 h, and
then stirred at room temperature overnight. The reaction solution
was cooled in ice–water bath, and acidiﬁed with HCl (3 mol/L).
The solvent was removed in vacuo and the residue was dissolved
in methanol to give a corresponding solution of crude 12.
A mixture of diphenylmethanone hydrazone (14.7 g, 75 mmol,
1.5 equiv.) and electrolytic manganese dioxide (13.04 g,
150 mmol, 3 equiv.) in petroleum ether (boiling range 30–60 1C)
was heated at reﬂux for 0.5 h, and the mixture was ﬁltered. The
ﬁltrate was added to the solution of 13 in methanol, and the
mixture was then stirred at room temperature until the purple color
disappeared, and then ﬁltered. The resulting ﬁltrate was evaporated
under reduced pressure to dryness. The residue was washed with
petroleum ether to afford crude compound 13 which was used
directly in the next step without further puriﬁcation.
To the mixture of crude 13 and anhydrous K2CO3 (3 equiv.) in
MeCN was added benzyl bromide (1 equiv.). The reaction mixture was
stirred at room temperature till the reaction was complete (checked by
TLC), then ﬁltered. The ﬁltrate was evaporated in vacuo to give the
crude product 14 as an oily residue, which was then dissolved in m-
cresol (10 mL), and the reaction mixture was stirred at 80 1C for 8–9 h.
It was then cooled, and methylisobutylketone (30 mL) was added. The
resulting solution was extracted with H2O (50 mL 3), and the
combined extracts were evaporated to dryness, and the residue was
puriﬁed through ﬂash chromatography over silica gel to give 1.5 g of
compound 15. White solid (1.5 g, 16.1%), mp 115117 1C; 1H NMR
(400 MHz, CD3OD): δ 7.267.44 (m, 5H), 4.384.47 (m, 1H),
4.084.13 (m, 1H), 3.723.74 (m, 1H), 3.153.25 (m, 2H),
2.763.18 (m, 3H), 2.592.70 (m, 1H), 2.322.49 (m, 3H),
1.852.25 (m, 6H), 1.391.72 (m, 7H); HRMS: calcd. for
C22H33N2O3 (MþH)þ 373.2491, found 373.2493.
4.2. Biological methods
4.2.1. Cell culture
Human liver cell line Huh7.5 cells (kindly provided by Vertex
Pharmaceuticals, Inc., Boston, MA) were cultured in Dulbecco's
modiﬁed eagle medium (DMEM) supplemented with 10%
Yinghong Li et al.312inactivated fetal bovine serum and 1% penicillin–streptomycin
(Invitrogen). Cells were digested with 0.05% trypsin–ethylene
diamine tetraacetic acid (EDTA) and split twice a week.
4.2.2. Anti-HCV effect in vitro
Huh7.5 cells were seeded into 96-well or 6-well plates (Costar) at a
density of 3 104 cells/cm2. After 24 h incubation, the cells were
infected with HCV viral stock (45 IU/cell) and simultaneously
treated with the test compounds at various concentrations or solvent
as control. The culture medium was removed after 72 h inoculation,
the intracellular total RNA (in 96-well plates) was extracted with
RNeasy Mini Kit (Qiagen), and total intracellular proteins (in 6-well
plates) were extracted with Cyto-Buster Protein Extraction Reagent
added with 1 mmol/L protease inhibitor cocktail. The intracellular
HCV RNA was quantiﬁed with a real time one-step reverse-
transcription polymerase chain reaction (RT-PCR).
4.2.3. Cytotoxicity assay
Huh7.5 cells were seeded into 96-well plates (Costar) at a density of
3 104 cells/cm2. After incubated for 24 h, fresh culture medium
containing test compounds at various concentrations were added.
Seventy-two hours later, cytotoxicity was evaluated with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
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